All In Biotech

Drug Trial Radar · NCT07370584

A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults

A Randomized, Vehicle-Controlled, Double-Masked Study of the Safety of IVMED-85 Ophthalmic Solution in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Feb 4, 2026

Primary completion

Apr 1, 2026

Study completion May 13, 2026

Sponsor

Lead sponsor
iVeena Delivery Systems, Inc.Industry
Sponsor type
Industry
Collaborators
Lexitas Pharma Services, Inc.
First posted
Jan 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this trial is to determine the safety of IVMED-85 eye drops in healthy adult subjects. Participants will be assigned to either the active or vehicle eyedrop group. The participants will receive eye drops twice daily for 6 weeks. Participants will not know which eyedrop they are taking.

Conditions

  • Safety Study

Interventions

  • IVMED-85 ophthalmic solutionDrug

    IVMED-85 ophthalmic solution (0.20 mg/mL), administer twice a day (morning and evening) in both eyes

  • Vehicle Ophthalmic SolutionDrug

    Vehicle ophthalmic solution, administer twice a day (morning and evening) in both eyes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual acuityTime frame: From enrollment to the end of treatment at 6 weeks
  2. Change in eye assessmentsTime frame: From enrollment to the end of treatment at 6 weeks
  3. Punctal stenosis or Bloody dischargeTime frame: From enrollment to the end of treatment at 6 weeks
  4. Change in ocular assessmentsTime frame: From enrollment to the end of treatment at 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Total Eye Care, P.A.

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.